Literature DB >> 30833579

Assessing metastatic potential of breast cancer cells based on EGFR dynamics.

Yen-Liang Liu1, Chao-Kai Chou2, Mirae Kim1, Rohan Vasisht1, Yu-An Kuo1, Phyllis Ang3, Cong Liu1, Evan P Perillo1, Yu-An Chen1, Katherine Blocher1, Hannah Horng4, Yuan-I Chen1, Duc Trung Nguyen1, Thomas E Yankeelov1,5,6,7,8, Mien-Chie Hung2,9, Andrew K Dunn1, Hsin-Chih Yeh10,11.   

Abstract

Derailed transmembrane receptor trafficking could be a hallmark of tumorigenesis and increased tumor invasiveness, but receptor dynamics have not been used to differentiate metastatic cancer cells from less invasive ones. Using single-particle tracking techniques, we  developed a phenotyping asssay named Transmembrane Receptor Dynamics (TReD), studied the dynamics of epidermal growth factor receptor (EGFR) in seven breast epithelial cell lines and developed a phenotyping assay named Transmembrane Receptor Dynamics (TReD). Here we show a clear evidence that increased EGFR diffusivity and enlarged EGFR confinement size in the plasma membrane (PM) are correlated with the enhanced metastatic potential in these cell lines. By comparing the TReD results with the gene expression profiles, we found a clear negative correlation between the EGFR diffusivities and the breast cancer luminal differentiation scores (r = -0.75). Upon the induction of epithelial-mesenchymal transition (EMT), EGFR diffusivity significantly increased for the non-tumorigenic MCF10A (99%) and the non-invasive MCF7 (56%) cells, but not for the highly metastatic MDA-MB-231 cell. We believe that the reorganization of actin filaments during EMT modified the PM structures, causing the receptor dynamics to change. TReD can thus serve as a new biophysical marker to probe the metastatic potential of cancer cells and even to monitor the transition of metastasis.

Entities:  

Year:  2019        PMID: 30833579      PMCID: PMC6399327          DOI: 10.1038/s41598-018-37625-0

Source DB:  PubMed          Journal:  Sci Rep        ISSN: 2045-2322            Impact factor:   4.379


  18 in total

1.  HSATII RNA is induced via a noncanonical ATM-regulated DNA damage response pathway and promotes tumor cell proliferation and movement.

Authors:  Maciej T Nogalski; Thomas Shenk
Journal:  Proc Natl Acad Sci U S A       Date:  2020-11-30       Impact factor: 11.205

2.  Increased expression of Profilin potentiates chemotherapeutic agent-mediated tumour regression.

Authors:  Shashank Saurav; Sunil Kumar Manna
Journal:  Br J Cancer       Date:  2022-01-12       Impact factor: 9.075

3.  Chitosan-Coated-PLGA Nanoparticles Enhance the Antitumor and Antimigration Activity of Stattic - A STAT3 Dimerization Blocker.

Authors:  Stephanie Sally Fong; Yiing Yee Foo; Wen Shang Saw; Bey Fen Leo; Yin Yin Teo; Ivy Chung; Boon Tong Goh; Misni Misran; Toyoko Imae; Chia-Ching Chang; Lip Yong Chung; Lik Voon Kiew
Journal:  Int J Nanomedicine       Date:  2022-01-11

4.  EMT changes actin cortex rheology in a cell-cycle-dependent manner.

Authors:  Kamran Hosseini; Annika Frenzel; Elisabeth Fischer-Friedrich
Journal:  Biophys J       Date:  2021-05-20       Impact factor: 3.699

5.  Tuning Hydrogel Adhesivity and Degradability to Model the Influence of Premetastatic Niche Matrix Properties on Breast Cancer Dormancy and Reactivation.

Authors:  Cindy J Farino Reyes; John H Slater
Journal:  Adv Biol (Weinh)       Date:  2022-03-11

6.  Spatial EGFR Dynamics and Metastatic Phenotypes Modulated by Upregulated EphB2 and Src Pathways in Advanced Prostate Cancer.

Authors:  Yen-Liang Liu; Aaron M Horning; Brandon Lieberman; Mirae Kim; Che-Kuang Lin; Chia-Nung Hung; Chih-Wei Chou; Chiou-Miin Wang; Chun-Lin Lin; Nameer B Kirma; Michael A Liss; Rohan Vasisht; Evan P Perillo; Katherine Blocher; Hannah Horng; Josephine A Taverna; Jianhua Ruan; Thomas E Yankeelov; Andrew K Dunn; Tim H-M Huang; Hsin-Chih Yeh; Chun-Liang Chen
Journal:  Cancers (Basel)       Date:  2019-12-01       Impact factor: 6.639

7.  Formation of an RNA Quadruplex-Duplex Hybrid in Living Cells between mRNA of the Epidermal Growth Factor Receptor (EGFR) and a G-Rich Antisense Oligoribonucleotide.

Authors:  Dorota Gudanis; Damian Kaniowski; Katarzyna Kulik; Daniel Baranowski; Zofia Gdaniec; Barbara Nawrot
Journal:  Cells       Date:  2020-10-29       Impact factor: 6.600

8.  3D tumor spheroid microarray for high-throughput, high-content natural killer cell-mediated cytotoxicity.

Authors:  Sneha Gopal; Seok-Joon Kwon; Bosung Ku; Dong Woo Lee; Jungeun Kim; Jonathan S Dordick
Journal:  Commun Biol       Date:  2021-07-21

9.  Ambrisentan, an endothelin receptor type A-selective antagonist, inhibits cancer cell migration, invasion, and metastasis.

Authors:  Lucy Kappes; Ruba L Amer; Sabine Sommerlatte; Ghada Bashir; Corinna Plattfaut; Frank Gieseler; Timo Gemoll; Hauke Busch; Abeer Altahrawi; Ashraf Al-Sbiei; Shoja M Haneefa; Kholoud Arafat; Lena F Schimke; Nadia El Khawanky; Kai Schulze-Forster; Harald Heidecke; Anja Kerstein-Staehle; Gabriele Marschner; Silke Pitann; Hans D Ochs; Antje Mueller; Samir Attoub; Maria J Fernandez-Cabezudo; Gabriela Riemekasten; Basel K Al-Ramadi; Otavio Cabral-Marques
Journal:  Sci Rep       Date:  2020-09-28       Impact factor: 4.379

10.  The efficacy of gefitinib supplementation for breast cancer: A meta-analysis of randomized controlled studies.

Authors:  Jing Ye; Tian Tian; Xiaopin Chen
Journal:  Medicine (Baltimore)       Date:  2020-10-23       Impact factor: 1.817

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.